Skip to main content
ArticleOPEN ACCESS

Correction: A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11 [Oncotarget., 9, (2018) (18811-18820)] doi 10.18632/oncotarget.24702

Oncotarget
DOI: 10.18632/oncotarget.25775
0Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Cite

CITATION STYLE

APA

Satake, H., Sunakawa, Y., Miyamoto, Y., Nakamura, M., Nakayama, H., Shiozawa, M., … Sekikawa, T. (2018, July 1). Correction: A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11 [Oncotarget., 9, (2018) (18811-18820)] doi 10.18632/oncotarget.24702. Oncotarget. Impact Journals LLC. https://doi.org/10.18632/oncotarget.25775

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free